Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination
- Conditions
- Multiple Myeloma
- Interventions
- Other: Bone marrow sampling
- Registration Number
- NCT05945524
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
- With multiple myeloma
- Who receive Teclistamab
- Consent form signed
- Patient under legal protection
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Analysis of bone marrow Bone marrow sampling Analysis of bone marrow in patients initiated treatment by Teclistamab for 18 cycles
- Primary Outcome Measures
Name Time Method Response to teclistamab at 12 weeks at day 1 Cycle 4 (each cycle is 28 days) response according to International Myeloma Working Group criteria
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (18)
Centre Léon Bérard
🇫🇷Lyon, France
Polyclinique du Parc Drevon
🇫🇷Dijon, France
CH Annecy Genevois
🇫🇷Epagny Metz- Tessy, France
CHU de Montpellier
🇫🇷Montpellier, France
Hôpital Saint-Louis
🇫🇷Paris, France
Hôpital Saint-Antoine
🇫🇷Paris, France
CHU de Caen
🇫🇷Caen, France
CHU d'Amiens
🇫🇷Amiens, France
CHU de Poitiers
🇫🇷Poitiers, France
CHU de Rennes
🇫🇷Rennes, France
CHU de Lille
🇫🇷Lille, France
Hôpital Necker
🇫🇷Paris, France
CHU de Bordeaux
🇫🇷Pessac, France
CHU de Lyon
🇫🇷Pierre-benite, France
CH Saint-Etienne
🇫🇷St Priest-en-jarez, France
CHU de Toulouse
🇫🇷Toulouse, France
CHU de Tours
🇫🇷Tours, France
CHRU Nancy
🇫🇷Vandoeuvre Les Nancy, France